An interventional study of Indego Therapy in Stroke, Brain Injuries, Traumatic and Brain Tumor Benign, sponsored by IRCCS San Raffaele Roma. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by IRCCS San Raffaele Roma · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Stroke by IRCCS San Raffaele Roma — 4 open to participants now, 5 under way, none of them phase 3. Stroke · IRCCS San Raffaele Roma.
Among the 12 studies in Stroke by IRCCS San Raffaele Roma, this one is one of 4 that started in 2020, is one of 9 with no phase, and was the 6th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →4 of the 12 studies in Stroke by IRCCS San Raffaele Roma are open now, in 6 countries. Recruiting first, the newest first:
IRCCS San Raffaele Roma · Sites in United States, Czechia, Italy and 3 more countries
Ages 18–85
IRCCS San Raffaele Roma · Sites in Italy
Ages 18+
IRCCS San Raffaele Roma · Sites in Italy
Ages 18+
IRCCS San Raffaele Roma · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2020.
This study's enrollment of 30 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 50 across the 9 interventional studies, 105 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele Roma is the lead sponsor of 71 studies on the registry; 25 are open to participants now.
3 of the studies in Stroke by IRCCS San Raffaele Roma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04559724IRCCS San Raffaele RomaGait Training Through a Novel Over-ground Wearable Robotic System in People With Pyramidal Hemisyndromes | 2026-12 |
| NCT07637123IRCCS San Raffaele RomaEvaluation of a Soft Elbow Exoskeleton and a Haptic Armband in Post-stroke and Parkinson's Disease Patients | 2026-12 |
| NCT06906588IRCCS San Raffaele RomaBilateral Robot-assisted Upper Extremity Rehabilitation on Motor Recovery in People With Subacute Stroke | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Stroke by IRCCS San Raffaele Roma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over-ground exoskeletons for gait rehabilitation are studied enough in people suffering spinal cord injury, and its clinical use is escalating in the industrialized countries. Nevertheless, studies on gait rehabilitation through exoskeletons in subjects with Pyramidal Hemisyndrome (PH) are recognized by GRADE as Low Quality of evidence.
This interventional longitudinal pilot study is aimed to investigate the feasibility, clinical effects, and compliance (from the experienced therapists (Indego Specialists)' point of view) of using an over-ground wearable robotic system (Indego) for gait rehabilitation of people with PH in the clinical practice.
Two substudies will be conducted with the following aims: to explore changes in the gait pattern and muscle activity following Indego-assisted gait rehabilitation through the kinematic gait analysis (in subjects able to walk) associated with surface electromyography (sEMG) of 4 muscle groups of the lower limbs; to identify prognostic factors for walking recovery, investigating also the effect of the treatment on functional connectivity through the electroencephalographic (EEG) analysis.
In order to satisfy the study aims, 30 subjects with PH and walking impairment will be recruited and assessed both clinically and instrumentally (in case of substudies) at the beginning (T0) and the end (T1) of the treatment period.
The primary objective of this interventional longitudinal pilot study is to investigate the feasibility of using an over-ground wearable robotic system (Indego) for gait rehabilitation of people with PH associated with the traditional rehabilitation.
Secondary objectives of the study are:
Two Sub-Studies (SS) will be conducted with the following aims:
30 subjects with PH and walking impairment who meet the research project inclusion and exclusion criteria will be recruited for this study. Patients will be evaluated at T0 and at T1. Demographic (gender, date of birth, height, weight, education, dominant side, work activity, presence of the social network, presence of architectural barriers at home) and clinical data (comorbidity, drug therapy, blood pressure, the cardiac frequency at rest, date of last acute event, number of previous neurological events, location of acute events) of all participants will be recorded at T0. In the case of Sub-Studies, 10 patients (able to walk fo 4 meters without aids but with supervision) for SS1 and 5 patients for SS2 following the first-ever monofocal cerebrovascular acute event will be recruited. These subjects will be assessed both clinically and instrumentally (SS1: through the gait analysis and sEMG; SS2: through the EEG) at T0 and T1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Possibility to keep the upright position for at least 1 minute with good cardiovascular compensation and:
Exclusion Criteria:
Impossibility to wear the robot:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC): * subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program; * Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program. * During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion.
Device: Indego Therapy
Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
Changes in 6 Minute Walk Test (6MWT)
The 6MWT measures the distance a subject covers during an indoor gait on a flat, hard surface in 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change in distance for people with sub-acute stroke is 60.98 meters. The 6MWT is a patient self-paced walk test and assesses the level of functional capacity. Patients are allowed to stop and rest during the test. However, the timer does not stop. If the patient is unable to complete the test, the time is stopped at that moment. The missing time and the reason of the stop are recorded.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in 10 Meter Walk Test (10MWT)
This test will assess the patient's speed during gait. Patients will be asked to walk at their preferred maximum and safe speed. Patients will be positioned 1 meter before the start line and instructed to walk 10 meters, and pass the end line approximately 1 meter after. The distance before and after the course is meant to minimize the effect of acceleration and deceleration. Time will be measured using a stopwatch and recorded to the one-hundredth of a second (ex: 2.15 s). The test will be recorded 3 times, with adequate rests between them. The average of the 3 times should be recorded.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Timed Up And Go (TUG)
The TUG is a test used to assess mobility, balance, and walking in people with balance impairments. The subject must stand up from a chair (which should not be leaned against a wall), walk a distance of 3 meters, turn around, walk back to the chair and sit down - all performed as quickly and as safely as possible. Time will be measured using a chronometer.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Modified Ashworth Scale (MAS)
The MAS is a 6 point ordinal scale used for grading hypertonia in individuals with neurological diagnoses. A score of 0 on the scale indicates no increase in tone while a score of 4 indicates rigidity. Tone is scored by passively moving the individual's limb and assessing the amount of resistance to movement felt by the examiner.
Time frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Trunk Control Test (TCT)
The TCT assesses the motor impairment in stroke patients and it's correlated with eventual walking ability. Testing is done with the patient lying on a bed: (1) roll to weak side. (2) roll to strong side. (3) balance in sitting position on the edge of the bed with the feet off the ground for at least 30. (4) sit up from lying down. Total score: 0-100.
Time frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Functional Ambulation Classification (FAC)
FAC is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device.
Time frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Barthel Index (BI)
The BI is a measure of Activity of Daily Living (ADL), which shows the degree of independence of a patient from any assistance. Each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses ten variables describing ADL and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Walking Handicap Scale (WHS)
WHS is a classification of 6 functional walking categories, considered as a participation category of the ICF because of its 3 items referred to community ambulation. The score ranges from 1 to 6, and do higher values represent a better outcome.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Motricity Index (MI)
The MI aims to evaluate lower limb motor impairment after stroke, administrated on both sides. Items to assess the lower limbs are 3, scoring from 0 to 33 each: (1) ankle dorsiflexion with foot in a plantar flexed position (2) knee extension with the foot unsupported and the knee at 90° (3) hip flexion with the hip at 90° moving the knee as close as possible to the chin. (no movement: 0, palpable flicker but no movement: 9, movement but not against gravity :14, movement against gravity movement against gravity: 19, movement against resistance: 25, normal:33) 1 leg score for each side = SUM (points for the 3 leg tests) + 1 Interpretation: minimum score: 0; maximum score:100
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Gait Analysis (GA)
Kinematic and kinetic gait parameters will be calculated from data acquired with a motion capture system (SMART-DX; BTSBioengneering, Italy). DAVIS HILL protocol will be applied. Each subject (able to walk) will perform at least 3 trials, each consisting of 3 meters self-paced speed walk under condition with shoes and orthoses/aids if needed.
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Electroencephalography (EEG)
EEG data will be recorded (250 Hz sampling rate) with a 128-electrode system placed on the scalp (10-10 augmented system) (Geodesic; ElectricalGeodesic, Inc .; Oregon, USA). The EEG signals, recorded during the entire test, will be involved in offline processing processes that will include a pre-processing for the removal of noisy channels (bad channel), filtering in the 0.3-45 Hz band, and removal of artifacts by means of the technique of Independent Component Analysis (ICA). Subsequently, the signals will be filtered by MATLAB in the bands of interest alpha and beta and segmented into epochs. Time-frequency algorithms will allow to characterize brain activity in response to motor tasks by calculating the event-related desynchronization/synchronization index (ERD / ERS). Acquisitions will be carried out in: relaxed sitting position (Open Eyes / Closed Eyes) for 2 min; standing position (Open Eyes) for 1 min, and during ankles flexion-extension (hip and knee in 90°).
Time frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Plan to share: No
Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 75 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion May 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS San Raffaele Roma